Propanc Biopharma Registers 2.5M Shares for Resale — Potential 71% Dilution Overhang from Toxic Preferred Stock

summarizeSummary

Propanc Biopharma filed an S-1 to register 2.5 million shares for resale by Hexstone Capital, a holder of Series C Preferred Stock with variable conversion terms that could lead to massive dilution at deeply discounted prices. The filing reveals a potential overhang of up to 9.5 million shares, threatening to overwhelm the current 3.5 million share float.

check_boxKey Events · Financing and Capital Events · PPCB

• 2.5M Share Resale Registration

  Hexstone Capital LLC is registering 2.5 million shares for resale, representing ~71% of the current 3.5 million shares outstanding. The company receives no proceeds from these sales.

• Toxic Conversion Terms

  Series C Preferred Stock converts at the lesser of $125.00 or 85% of the lowest trading price during a measurement period, with a $12.50 floor. At today's $1.45 stock price, the effective conversion price could be as low as $1.23, enabling Hexstone to acquire shares at a steep discount.

• 9.5M Share Reserve Requirement

  The company is obligated to reserve 9.5 million shares for potential Series C conversions — nearly 3x the current outstanding shares — indicating a much larger potential dilution overhang beyond the 2.5 million shares being registered.

• Going Concern Warning Reiterated

  The filing repeats the going concern warning, with an accumulated deficit of $140.8 million and only $443,702 in cash as of March 31, 2026, despite raising $4.3 million in financing during the nine months ended March 31, 2026.

auto_awesomeAnalysis · PPCB · Life Sciences

This S-1 registers 2.5 million shares for resale by Hexstone Capital, a holder of Series C Preferred Stock with deeply discounted variable conversion terms. The conversion price is the lesser of $125.00 or 85% of the lowest trading price during a measurement period, with a $12.50 floor — at today's $1.45 stock price, the effective conversion price could be as low as $1.23, enabling Hexstone to acquire shares at a massive discount and sell them into the market. The company must reserve 9.5 million shares for potential conversions, signaling a much larger overhang than the 2.5 million shares being registered. With only 3.5 million shares outstanding, full conversion and resale could dilute existing holders by over 70%. The company receives no proceeds from these sales, and the registration facilitates Hexstone's exit, creating persistent selling pressure. This comes amid a going concern warning, a recent reverse split, and a history of toxic financing — the filing confirms the company remains in a death-spiral financing cycle.